Adicet Bio Says FDA Has Granted Fast Track Designation To ADI-001 For Potential Treatment Of Relapsed/Refractory Class III Or Class IV Lupus Nephritis
Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.